Table 3 Logistic regression analyses of ancillary features in LI-RADS v2018 for all lesions
Variables | Univariable analysis | Multivariable analysis | ||||
|---|---|---|---|---|---|---|
Beta | OR (95%CI) | P | aBeta | aOR (95%CI) | aP | |
Nodule-in-nodule architecture | -1.40 | 0.25 (0.10–0.59) | 0.002 | -1.34 | 0.26 (0.06–1.13) | 0.073 |
Nonenhancing “capsule” | -13.92 | 0.00 (0.00 - Inf) | 0.978 | |||
Mosaic architecture | -17.04 | 0.00 (0.00 - Inf) | 0.979 | |||
Blood products in mass | -17.11 | 0.00 (0.00 - Inf) | 0.974 | |||
Fat in mass | 0.83 | 2.29 (1.35–3.86) | 0.002 | |||
Subthreshold growth | 14.22 | 1505228.15 (0.00 - Inf) | 0.979 | |||
Restricted diffusion | 1.59 | 4.92 (3.11–7.78) | < 0.001 | 1.81 | 6.11 (2.56–14.61) | < 0.001 |
Mild–moderate T2 hyperintensity | -0.05 | 0.96 (0.51–1.80) | 0.888 | 1.57 | 4.79 (1.62–14.14) | 0.005 |
Coronal enhancement | 1.45 | 4.27 (2.81–6.49) | < 0.001 | |||
Fat sparing | 0.10 | 1.11 (0.58–2.11) | 0.756 | |||
Iron sparing | -2.10 | 0.12 (0.02–0.94) | 0.043 | -2.03 | 0.13 (0.01–1.18) | 0.070 |
Transitional-phase hypointensity | -1.26 | 0.28 (0.16–0.49) | < 0.001 | -0.95 | 0.39 (0.16–0.92) | 0.032 |
Hepatobiliary-phase hypointensity | 0.69 | 1.99 (1.20–3.29) | 0.007 | |||
Parallels blood pool enhancement | 2.35 | 10.48 (2.99–36.75) | < 0.001 | |||
Undistorted vessels | -1.78 | 0.17 (0.02–1.32) | 0.090 | -1.74 | 0.18 (0.02–1.70) | 0.133 |
Marked T2 hyperintensity | 3.34 | 28.29 (8.55–93.66) | < 0.001 | 2.96 | 19.22 (3.38–109.24) | < 0.001 |
HBP isointensity | 2.50 | 12.24 (4.61–32.47) | < 0.001 | 1.72 | 5.57 (1.44–21.56) | 0.013 |